LB Pharmaceuticals
LBRX
68 hedge funds and large institutions have $552M invested in LB Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 13 increasing their positions, 12 reducing their positions, and 16 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
106% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 16
75% more capital invested
Capital invested by funds: $315M → $552M (+$237M)
28% more funds holding
Funds holding: 53 → 68 (+15)
8% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 12
1.19% less ownership
Funds ownership: 99.18% → 97.99% (-1.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$22.1M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.4M |
| 3 |
JP Morgan Chase
New York
|
+$10.1M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$7.54M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$7.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$8.5M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$6.81M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.44M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.74M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$4.15M |
LBRX Hedge Fund Activity: Q4 2025 in Review
68 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in LB Pharmaceuticals (LBRX) for Q4 2025, worth a combined $552M — up 75% from $315M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new LBRX positions and 16 closed out — a net gain of 17 holders — while 13 added to existing stakes and 12 trimmed.
The largest buyer was BlackRock, adding an estimated $22.1M. The largest seller was Millennium Management, exiting entirely with an estimated $8.5M sold.
- 68 institutional investors held LB Pharmaceuticals (LBRX) as of Q4 2025, up from 53 in Q3 2025.
- Funds reported $552M of LB Pharmaceuticals stock for Q4 2025, up 75% quarter-over-quarter.
- 33 funds opened new LB Pharmaceuticals positions in Q4 2025 and 16 closed out, a net change of +17 holders.
- The largest LB Pharmaceuticals buyer in Q4 2025 was BlackRock, an estimated $22.1M added.
- The largest LB Pharmaceuticals seller in Q4 2025 was Millennium Management, an estimated $8.5M sold.
Based on aggregated 13F filings for Q4 2025.